ALF Platform
COVID-19
Key Facts
About Senzo
Senzo is a private, pre-revenue diagnostics company pioneering a high-sensitivity lateral flow technology designed to bridge the gap between laboratory PCR and rapid antigen tests. Its core innovation, the Amplified Lateral Flow (ALF) platform, claims over 10,000 times more sensitivity than standard lateral flow tests and accuracy comparable to PCR, targeting the WHO's A.S.S.U.R.E.D. criteria for ideal point-of-care diagnostics. The company is advancing a pipeline of tests for major infectious diseases and has secured strategic manufacturing partnerships and funding to commercialize its platform for both professional and home use.
View full company profileAbout Senzo
Senzo is a private, pre-revenue diagnostics company pioneering a high-sensitivity lateral flow technology designed to bridge the gap between laboratory PCR and rapid antigen tests. Its core innovation, the Amplified Lateral Flow (ALF) platform, claims over 10,000 times more sensitivity than standard lateral flow tests and accuracy comparable to PCR, targeting the WHO's A.S.S.U.R.E.D. criteria for ideal point-of-care diagnostics. The company is advancing a pipeline of tests for major infectious diseases and has secured strategic manufacturing partnerships and funding to commercialize its platform for both professional and home use.
View full company profileAbout Senzo
Senzo is a private, pre-revenue diagnostics company pioneering a high-sensitivity lateral flow technology designed to bridge the gap between laboratory PCR and rapid antigen tests. Its core innovation, the Amplified Lateral Flow (ALF) platform, claims over 10,000 times more sensitivity than standard lateral flow tests and accuracy comparable to PCR, targeting the WHO's A.S.S.U.R.E.D. criteria for ideal point-of-care diagnostics. The company is advancing a pipeline of tests for major infectious diseases and has secured strategic manufacturing partnerships and funding to commercialize its platform for both professional and home use.
View full company profileAbout Senzo
Senzo is a private, pre-revenue diagnostics company pioneering a high-sensitivity lateral flow technology designed to bridge the gap between laboratory PCR and rapid antigen tests. Its core innovation, the Amplified Lateral Flow (ALF) platform, claims over 10,000 times more sensitivity than standard lateral flow tests and accuracy comparable to PCR, targeting the WHO's A.S.S.U.R.E.D. criteria for ideal point-of-care diagnostics. The company is advancing a pipeline of tests for major infectious diseases and has secured strategic manufacturing partnerships and funding to commercialize its platform for both professional and home use.
View full company profileAbout Senzo
Senzo is a private, pre-revenue diagnostics company pioneering a high-sensitivity lateral flow technology designed to bridge the gap between laboratory PCR and rapid antigen tests. Its core innovation, the Amplified Lateral Flow (ALF) platform, claims over 10,000 times more sensitivity than standard lateral flow tests and accuracy comparable to PCR, targeting the WHO's A.S.S.U.R.E.D. criteria for ideal point-of-care diagnostics. The company is advancing a pipeline of tests for major infectious diseases and has secured strategic manufacturing partnerships and funding to commercialize its platform for both professional and home use.
View full company profileAbout Senzo
Senzo is a private, pre-revenue diagnostics company pioneering a high-sensitivity lateral flow technology designed to bridge the gap between laboratory PCR and rapid antigen tests. Its core innovation, the Amplified Lateral Flow (ALF) platform, claims over 10,000 times more sensitivity than standard lateral flow tests and accuracy comparable to PCR, targeting the WHO's A.S.S.U.R.E.D. criteria for ideal point-of-care diagnostics. The company is advancing a pipeline of tests for major infectious diseases and has secured strategic manufacturing partnerships and funding to commercialize its platform for both professional and home use.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |
| UOL COVID-19 Test | Uh-Oh Labs | Approved |
| Lagevrio (molnupiravir) | Ridgeback Biotherapeutics | Approved/EUA |
| CVXGA | CyanVac | Phase 2 |